• Please choose what you believe to be the correct answer - both questions require a response to proceed.


  • A patient with CD was previously in a clinical study and was found to have the human leukocyte variant HLA-DQA1*05. The patient did not respond to initial treatment with 5-aminosalycilate and has moderately severe disease. Which of the following best describes an appropriate next treatment option, based on this information and the results of the 2020 PANTS (Personalizing Anti-TNF Therapy in Crohn’s Disease) trial? *